ACN Newswire
HONG KONG, Mar 25, 2025 – (ACN Newswire) – CanSino Biologics Inc. (Stock Code: 688185.SH, 6185.HK, “CanSinoBIO” or the “Company”), a leading player in China’s vaccine industry, achieved significant revenue growth in 2024, driven by continuous R&D innovation and strong commercial capabilities.In 2024, CanSinoBIO reported a total revenue of RMB 846 million…
Read More
Revenue Soars with 137% Year-on-Year Growth, Multiple Products Poised for Launch, CanSinoBIO’s Growth Momentum Strong
Michele Klemp
21:19
HONG KONG, Mar 25, 2025 – (ACN Newswire) – CanSino Biologics Inc. (Stock Code: 688185.SH, 6185.HK, “CanSinoBIO” or the “Company”), a leading player in China’s vaccine industry, achieved significant revenue growth in 2024, driven by continuous R&D innovation and strong commercial capabilities.In 2024, CanSinoBIO reported a total revenue of RMB 846 million…
